Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP229] to PTEN (phospho T366)
- Suitable for: WB, IHC-P, Dot blot
- Reacts with: Mouse, Rat, Human
Product nameAnti-PTEN (phospho T366) antibody [EP229]
See all PTEN primary antibodies
DescriptionRabbit monoclonal [EP229] to PTEN (phospho T366)
Specificityab109454 only detects PTEN phosphorylated on T366.
Tested applicationsSuitable for: WB, IHC-P, Dot blotmore details
Unsuitable for: Flow Cyt
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human PTEN (phospho T366).
- WB: Mouse brain tissue lysate and C6 cell lysate treated with Calyculin A. IHC-P: Human breast ductal carcinoma tissue.
PTEN is a protein implicated in several disease, including certain cancers and neurological diseases. PTEN is expressed ubiquitously throughout the body and acts as a phosphatase to dephosphorylate phosphatidylinositol (3,4,5)-trisphosphate. This is important in the inhibition of the Akt signalling pathway, which plays an important role in regulating cellular behaviours such as cell growth, survival, and migration.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.5% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab109454 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 54 kDa (predicted molecular weight: 47 kDa).|
|IHC-P||1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
|Dot blot||Use at an assay dependent concentration.|
FunctionTumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement.
Isoform alpha: Functional kinase, like isoform 1 it antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in mitochondrial energetic metabolism by promoting COX activity and ATP production, via collaboration with isoform 1 in increasing protein levels of PINK1.
Tissue specificityExpressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.
Involvement in diseaseCowden syndrome 1
Squamous cell carcinoma of the head and neck
PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.
VACTERL association with hydrocephalus
A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.
Sequence similaritiesContains 1 C2 tensin-type domain.
Contains 1 phosphatase tensin-type domain.
DomainThe C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function.
modificationsConstitutively phosphorylated by CK2 under normal conditions. Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding. Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from ubiquitin-mediated degradation probably by inhibiting its binding to NEDD4. Phosphorylation by ROCK1 is essential for its stability and activity. Phosphorylation by PLK3 promotes its stability and prevents its degradation by the proteasome.
Monoubiquitinated; monoubiquitination is increased in presence of retinoic acid. Deubiquitinated by USP7; leading to its nuclear exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated by XIAP/BIRC4.
Cellular localizationSecreted. May be secreted via a classical signal peptide and reenter into cells with the help of a poly-Arg motif and Cytoplasm. Nucleus. Nucleus, PML body. Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies. XIAP/BIRC4 promotes its nuclear localization.
- Information by UniProt
- 10q23del antibody
- BZS antibody
- DEC antibody
All lanes : Anti-PTEN (phospho T366) antibody [EP229] (ab109454) at 1/20000 dilution
Lane 1 : Untreated Hela whole cell lysate
Lane 2 : HeLa treated with Calyculin A whole cell lysate
Lane 3 : HeLa whole cell lysate treated with Calyculin A and phosphatase on the membrane
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 47 kDa
Exposure time: 1 minute
Blocking and dilution buffer: 5% NFDM/TBST.
Dot blot analysis of PTEN (pT366+ pS370) peptide (Lane 1), PTEN (pS370) peptide (Lane 2), PTEN (pT366) peptide (Lane 3), and PTEN non-phospho peptide (Lane 4) labelling PTEN phospho T366 with ab109454 at a dilution of 1/1000. ab97051 (Peroxidase conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/100000.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 10 seconds.
ab109454 at 1/100 dilution staining PTEN in Human breast ductal carcinoma by Immunohistochemistry, Paraffin-embedded tissue.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ab109454 has been referenced in 10 publications.
- Stump B et al. Glycogen synthase kinase 3-ß inhibition induces lymphangiogenesis through ß-catenin-dependent and mTOR-independent pathways. PLoS One 14:e0213831 (2019). PubMed: 30964887
- Engqvist H et al. Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas. BMC Cancer 19:928 (2019). PubMed: 31533654
- Gong L et al. miR-222 promotes invasion and migration of ovarian carcinoma by targeting PTEN. Oncol Lett 16:984-990 (2018). PubMed: 29963173
- Yang S et al. MicroRNA-30a-3p overexpression improves sepsis-induced cell apoptosis in vitro and in vivo via the PTEN/PI3K/AKT signaling pathway. Exp Ther Med 15:2081-2087 (2018). PubMed: 29434809
- Li BH et al. Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway. Med Sci Monit 24:8105-8114 (2018). PubMed: 30418964
- Dai Z et al. Knockdown of PREX2a inhibits the malignant phenotype of osteosarcoma cells. Mol Med Rep 13:1930-6 (2016). PubMed: 26718453
- He S et al. Upregulation of PREX2 promotes the proliferation and migration of hepatocellular carcinoma cells via PTEN-AKT signaling. Oncol Lett 11:2223-2228 (2016). Human . PubMed: 26998152
- Yang J et al. PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway. Oncol Lett 12:1139-1143 (2016). WB ; Human . PubMed: 27446408
- Jang HD et al. PTEN regulation by the Akt/GSK-3ß axis during RANKL signaling. Bone 55:126-31 (2013). WB ; Mouse . PubMed: 23419777
- Xu D et al. Regulation of PTEN stability and activity by Plk3. J Biol Chem 285:39935-42 (2010). PubMed: 20940307